WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia

WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia

October 18, 2007

     SHANGHAI, China, Oct. 18 /Xinhua-PRNewswire/ -- WuXi
PharmaTech 
(NYSE: WX), China's premier provider of pharmaceutical
R&D outsourcing services announced today that it has
been nominated the winner of Deloitte Technology Fast 50
China 2007, a ranking of the fastest growing technology
companies in China as recognized by Deloitte Touche
Tohmatsu (Deloitte).

    (Logo: http://www.xprn.com/xprn/sa/200708281726-min.jpg
)

     The Deloitte Technology Fast 50 China program is an
annual award program that ranks technology, media, and
telecommunications companies located in Mainland China and
Hong Kong. According to Deloitte, winners are selected
based on their average revenue growth rates over the last
three years. WuXi PharmaTech has been included on such a
high-profile list for three consecutive years since
Deloitte China launched this award program in 2005.
Participants in the Deloitte Technology Fast 50 China
program will automatically qualify for participation in the
Deloitte Technology Fast 500 Asia Pacific 2007 program,
which annually recognizes the 500 fastest growing
technology companies in Asia Pacific. This will be the
fourth consecutive year that WuXi PharmaTech wins such a
prestigious award.

     "We're honored to receive such a distinguished
award once again in recognition of our ongoing
success," commented Dr. Ge Li, Chairman and CEO of
WuXi PharmaTech. "The award reflects our consistent
high operation standards and transparency, and tireless
dedication to customer satisfaction. In 2007 we continued
to expand service offering capabilities and capacities to
offer more value-added and responsive services to our
collaborative partners."

     About WuXi PharmaTech

     Founded in 2000, Shanghai-based WuXi PharmaTech is the
leading 
China-based pharmaceutical and biotechnology R&D
outsourcing company. As a research- driven and
customer-focused company, WuXi PharmaTech provides
pharmaceutical and biotechnology companies a broad and
integrated portfolio of laboratory and research
manufacturing services throughout the drug discovery and
development process. WuXi PharmaTech's services are
designed to assist its global partners in shortening the
cycle and lowering the cost of drug discovery and
development by providing cost-effective and efficient
outsourcing solutions that save its customers both time and
money. Its operations are grouped into two segments:
laboratory services, consisting of discovery chemistry,
service biology, analytical, toxicology, pharmaceutical
development and process development services, and
manufacturing, focusing on manufacturing of advanced
intermediates and active pharmaceutical ingredients for
R&D use. In 2006, WuXi PharmaTech provided services to
70 pharmaceutical and biotechnology customers, including
nine of the top ten pharmaceutical companies in the world,
as measured by 2006 total revenues. For more information,
please visit: http://www.wuxipharmatech.com .


    For more information, please contact:

     Sherry Shao
     Tel:   [phone]
     Email: [e-mail]